Coronary drug-eluting stents: From design optimization to newer strategies

Journal of Biomedical Materials Research - Part A

Volumn 102, Issue 5, 2014, Pages 1625-1640

  Sun, Daming ^a   Zheng, Yiming ^a   Yin, Tieying ^a   Tang, Chaojun ^a   Yu, Qingsong ^b   Wang, Guixue ^a  

^a CHONGQING UNIVERSITY   (China)

^b University of Missouri   (United States)

Author keywords

biodegradable stent; drug eluting stent; in stent restenosis; stent thrombosis

Indexed keywords

ARTIFICIAL ORGANS; BIODEGRADABLE POLYMERS; DESIGN; DISEASES; FUNCTIONAL POLYMERS; OPTIMIZATION;

BIODEGRADABLE STENTS; CORONARY ARTERY DISEASE; DEGRADABLE POLYMERS; DESIGN OPTIMIZATION; DRUG-ELUTING STENTS; ENDOTHELIALIZATION; IN-STENT RESTENOSIS; STENT THROMBOSIS;

STENTS;

BIOABSORBABLE POLYMER COATED DRUG ELUTING STENT; BIOCOMPATIBILITY; BIODEGRADABLE STENT; BIODEGRADATION; CORONARY STENT; DRUG ELUTING STENT; HUMAN; IRON BASED BIODEGRADABLE STENT; MAGNESIUM BASED BIODEGRADABLE STENT; MATERIAL COATING; POLYMER BASED BIODEGRADABLE STENT; POLYMER FREE DRUG ELUTING STENT; RESTENOSIS; REVIEW; STENT; THERAPY EFFECT; CORONARY BLOOD VESSEL; PHYSIOLOGY; PROCEDURES; PROSTHESIS;

CORONARY VESSELS; DRUG-ELUTING STENTS; HUMANS; PROSTHESIS DESIGN;

EID: 84897111402     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.34806     Document Type: Review

References (110)

1. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P,. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331: 489-495. (Pubitemid 24256751)
2. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M,. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994; 331: 496-501. (Pubitemid 24256752)
3. Holmes DR Jr, Hirshfeld J Jr, Faxon D, Vlietstra RE, Jacobs A, King SB, 3rd. ACC Expert Consensus document on coronary artery stents. Document of the American College of Cardiology. J Am Coll Cardiol 1998; 32: 1471-1482.
4. Caixeta A, Leon MB, Lansky AJ, Nikolsky E, Aoki J, Moses JW, Schofer J, Morice MC, Schampaert E, Kirtane AJ, Popma JJ, Parise H, Fahy M, Mehran R,. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents. J Am Coll Cardiol 2009; 54: 894-902.
5. Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R,. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol 2010; 56: 1897-1907.
6. Maisel WH,. Unanswered questions - drug-eluting stents and the risk of late thrombosis. N Engl J Med 2007; 356: 981-984. (Pubitemid 46376797)
7. Commandeur S, van Beusekom HM, van der Giessen WJ,. Polymers, drug release, and drug-eluting stents. J Interv Cardiol 2006; 19: 500-506. (Pubitemid 44722241)
8. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE,. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323. (Pubitemid 37186209)
9. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME,. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231. (Pubitemid 38067635)
10. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, Menichelli M, Sabate M, Suttorp MJ, Baumgart D, Seyfarth M, Pfisterer ME, Schomig A,. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356: 1030-1039. (Pubitemid 46376803)
11. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L,. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007; 356: 1009-1019. (Pubitemid 46376801)
12. Shuchman M,. Trading restenosis for thrombosis? New questions about drug-eluting stents. N Engl J Med 2006; 355: 1949-1952. (Pubitemid 44708012)
13. Kuchulakanti PK, Chu WW, Torguson R, Ohlmann P, Rha SW, Clavijo LC, Kim SW, Bui A, Gevorkian N, Xue Z, Smith K, Fournadjieva J, Suddath WO, Satler LF, Pichard AD, Kent KM, Waksman R,. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 2006; 113: 1108-1113.
14. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R,. Pathological correlates of late drug-eluting stent thrombosis: Strut coverage as a marker of endothelialization. Circulation 2007; 115: 2435-2441. (Pubitemid 46717966)
15. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD,. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious? Circulation 2004; 109: 701-705. (Pubitemid 38222887)
16. Ako J, Bonneau HN, Honda Y, Fitzgerald PJ,. Design criteria for the ideal drug-eluting stent. Am J Cardiol 2007; 100: 3M-9M.
17. Martin DM, Boyle FJ,. Drug-eluting stents for coronary artery disease: A review. Med Eng Phys 2011; 33: 148-163.
18. Mortier P, Verdonck PR,. Stent design matters: Insights from virtual bench testing. Expert Rev Cardiovasc Ther 2010; 8: 613-615.
19. Briguori C, Sarais C, Pagnotta P, Liistro F, Montorfano M, Chieffo A, Sgura F, Corvaja N, Albiero R, Stankovic G, Toutoutzas C, Bonizzoni E, Di Mario C, Colombo A,. In-stent restenosis in small coronary arteries: Impact of strut thickness. J Am Coll Cardiol 2002; 40: 403-409. (Pubitemid 34833152)
20. Lau KW, Johan A, Sigwart U, Hung JS,. A stent is not just a stent: Stent construction and design do matter in its clinical performance. Singapore Med J 2004; 45: 305-311; quiz 312.
21. McLean DR, Eiger NL,. Stent design: implications for restenosis. Rev Cardiovasc Med 2002; 3 Suppl 5: S16-S22.
22. Arakawa K, Isoda K, Sugiyabu Y, Fukuda M, Nishizawa K, Shibuya T, Nakamura H,. Intimal proliferation after stenting reflected by increased stent-to-vessel cross-sectional area ratio: Serial intravascular ultrasound study. J Cardiol 1998; 32: 379-389. (Pubitemid 29016890)
23. Fontaine AB, Spigos DG, Eaton G, Das Passos S, Christoforidis G, Khabiri H, Jung S,. Stent-induced intimal hyperplasia: Are there fundamental differences between flexible and rigid stent designs? J Vasc Interv Radiol 1994; 5: 739-744.
24. Yoshitomi Y, Kojima S, Yano M, Sugi T, Matsumoto Y, Saotome M, Tanaka K, Endo M, Kuramochi M,. Does stent design affect probability of restenosis? A randomized trial comparing Multilink stents with GFX stents. Am Heart J 2001; 142: 445-451. (Pubitemid 32801628)
25. Hoffmann R, Mintz GS, Haager PK, Bozoglu T, Grube E, Gross M, Beythien C, Mudra H, vom Dahl J, Hanrath P,. Relation of stent design and stent surface material to subsequent in-stent intimal hyperplasia in coronary arteries determined by intravascular ultrasound. Am J Cardiol 2002; 89: 1360-1364. (Pubitemid 34607774)
26. Hoye A, Iakovou I, Ge L, van Mieghem CA, Ong AT, Cosgrave J, Sangiorgi GM, Airoldi F, Montorfano M, Michev I, Chieffo A, Carlino M, Corvaja N, Aoki J, Rodriguez Granillo GA, Valgimigli M, Sianos G, van der Giessen WJ, de Feyter PJ, van Domburg RT, Serruys PW, Colombo A,. Long-term outcomes after stenting of bifurcation lesions with the «crush» technique: Predictors of an adverse outcome. J Am Coll Cardiol 2006; 47: 1949-1958.
27. Craig C, Friend C, Edwards M, Cornish L, Gokcen N,. Mechanical properties and microstructure of platinum enhanced radiopaque stainless steel (PERSS) alloys. J Alloy Compd 2003; 361: 187-199.
28. Pache J, Kastrati A, Mehilli J, Schuhlen H, Dotzer F, Hausleiter J, Fleckenstein M, Neumann FJ, Sattelberger U, Schmitt C, Muller M, Dirschinger J, Schomig A,. Intracoronary stenting and angiographic results: Strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol 2003; 41: 1283-1288. (Pubitemid 36438988)
29. Doi H, Maehara A, Mintz GS, Tsujita K, Kubo T, Castellanos C, Liu J, Yang J, Oviedo C, Aoki J, Franklin-Bond T, Dasgupta N, Lansky AJ, Dangas GD, Stone GW, Moses JW, Mehran R, Leon MB,. Classification and potential mechanisms of intravascular ultrasound patterns of stent fracture. Am J Cardiol 2009; 103: 818-823.
30. Manola S, Pintaric H, Pavlovic N, Stambuk K,. Coronary artery stent fracture with aneurysm formation and in-stent restenosis. Int J Cardiol 2010; 140: e36-e39.
31. Yamada KP, Koizumi T, Yamaguchi H, Kaneda H, Bonneau HN, Honda Y, Fitzgerald PJ,. Serial angiographic and intravascular ultrasound analysis of late stent strut fracture of sirolimus-eluting stents in native coronary arteries. Int J Cardiol 2008; 130: 255-259.
32. Bilen E, Saatci Yasar A, Bilge M, Karakas F, Kirbas O, Ipek G,. Acute coronary syndrome due to complete bare metal stent fracture in the right coronary artery. Int J Cardiol 2010; 139: e44-e46.
33. Lee MS, Jurewitz D, Aragon J, Forrester J, Makkar RR, Kar S,. Stent fracture associated with drug-eluting stents: Clinical characteristics and implications. Catheter Cardiovasc Interv 2007; 69: 387-394. (Pubitemid 46339280)
34. Umeda H, Gochi T, Iwase M, Izawa H, Shimizu T, Ishiki R, Inagaki H, Toyama J, Yokota M, Murohara T,. Frequency, predictors and outcome of stent fracture after sirolimus-eluting stent implantation. Int J Cardiol 2009; 133: 321-326.
35. Papafaklis MI, Chatzizisis YS, Naka KK, Giannoglou GD, Michalis LK,. Drug-eluting stent restenosis: Effect of drug type, release kinetics, hemodynamics and coating strategy. Pharmacol Ther 2012; 134: 43-53.
36. Grube E, Gerckens U, Muller R, Bullesfeld L,. Drug eluting stents: Initial experiences. Z Kardiol 2002; 91 (Suppl 3): 44-48. (Pubitemid 34809724)
37. Thomson AW, Bonham CA, Zeevi A,. Mode of action of tacrolimus (FK506): Molecular and cellular mechanisms. Ther Drug Monit 1995; 17: 584-591.
38. Deconinck E, Sohier J, De Scheerder I, Van den Mooter G,. Pharmaceutical aspects of drug eluting stents. J Pharm Sci 2008; 97: 5047-5060.
39. Yin TY, Wang GX, Zhang DC, Du DY, Li ZG, Luo LL, Hou YB, Wang YZ, Zhao JB,. Endothelialization and in-stent restenosis on the surface of glycoprotein IIIa monoclonal antibody eluting stent. J Biomed Mater Res A 2012; 100: 1398-1406.
40. Aggarwal RK, Ireland DC, Azrin MA, Ezekowitz MD, de Bono DP, Gershlick AH,. Antithrombotic potential of polymer-coated stents eluting platelet glycoprotein IIb/IIIa receptor antibody. Circulation 1996; 94: 3311-3317. (Pubitemid 26427503)
41. Byrne RA, Joner M, Kastrati A,. Polymer coatings and delayed arterial healing following drug-eluting stent implantation. Minerva Cardioangiol 2009; 57: 567-584.
42. Cook S, Ladich E, Nakazawa G, Eshtehardi P, Neidhart M, Vogel R, Togni M, Wenaweser P, Billinger M, Seiler C, Gay S, Meier B, Pichler WJ, Juni P, Virmani R, Windecker S,. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation 2009; 120: 391-399.
43. Nakazawa G, Ladich E, Finn AV, Virmani R,. Pathophysiology of vascular healing and stent mediated arterial injury. EuroIntervention 2008; 4 (Suppl C): C7-C10.
44. Rasmussen K, Maeng M, Kaltoft A, Thayssen P, Kelbaek H, Tilsted HH, Abildgaard U, Christiansen EH, Engstrom T, Krusell LR, Ravkilde J, Hansen PR, Hansen KN, Abildstrom SZ, Aaroe J, Jensen JS, Kristensen SD, Botker HE, Madsen M, Johnsen SP, Jensen LO, Sorensen HT, Thuesen L, Lassen JF,. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): A randomised controlled superiority trial. Lancet 2010; 375: 1090-1099.
45. Leon MB, Mauri L, Popma JJ, Cutlip DE, Nikolsky E, O'Shaughnessy C, Overlie PA, McLaurin BT, Solomon SL, Douglas JS Jr, Ball MW, Caputo RP, Jain A, Tolleson TR, Reen BM 3rd, Kirtane AJ, Fitzgerald PJ, Thompson K, Kandzari DE,. A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol 2010; 55: 543-554.
46. Meredith IT, Worthley S, Whitbourn R, Walters D, Popma J, Cutlip D, Fitzgerald P,. The next-generation Endeavor Resolute stent: 4-month clinical and angiographic results from the Endeavor Resolute first-in-man trial. EuroIntervention 2007; 3: 50-53.
47. Udipi K, Melder RJ, Chen M, Cheng P, Hezi-Yamit A, Sullivan C, Wong J, Wilcox J,. The next generation endeavor resolute stent: Role of the BioLinx Polymer System. EuroIntervention 2007; 3: 137-139.
48. Meredith IT, Worthley S, Whitbourn R, Walters DL, McClean D, Horrigan M, Popma JJ, Cutlip DE, DePaoli A, Negoita M, Fitzgerald PJ,. Clinical and angiographic results with the next-generation resolute stent system: A prospective, multicenter, first-in-human trial. JACC Cardiovasc Interv 2009; 2: 977-985.
49. Nikolsky E, Endeavor Resolute: Clinical results to 36 months. Presented at: TCT Conference. San Francisco, CA, USA; 2009. p 21-25.
50. Liu TY, Lin WC, Huang LY, Chen SY, Yang MC,. Surface characteristics and hemocompatibility of PAN/PVDF blend membranes. Polym Adv Technol 2005; 16: 413-419.
51. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, Wilson PS, Skorija K, Cheng Q, Xu X,. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008; 52: 333.
52. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ,. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010; 362: 1663-1674.
53. Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, Smits PC,. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): A randomised trial. Lancet 2010; 375: 201-209.
54. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R,. Vascular responses to drug eluting stents: Importance of delayed healing. Arterioscler Thromb Vasc Biol 2007; 27: 1500-1510. (Pubitemid 46986103)
55. van der Giessen WJ, Lincoff AM, Schwartz RS, van Beusekom HM, Serruys PW, Holmes DR, Jr., Ellis SG, Topol EJ,. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996; 94: 1690-1697. (Pubitemid 26320276)
56. Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, Davies S, van Geuns RJ, Eerdmans P, van Es GA, Meier B, Juni P,. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): A randomised non-inferiority trial. Lancet 2008; 372: 1163-1173.
57. Chevalier B, Silber S, Park SJ, Garcia E, Schuler G, Suryapranata H, Koolen J, Hauptmann KE, Wijns W, Morice MC, Carrie D, van Es GA, Nagai H, Detiege D, Paunovic D, Serruys PW,. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberte paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: The NOBORI 1 trial - Phase 2. Circ Cardiovasc Interv 2009; 2: 188-195.
58. Ormiston JA, Abizaid A, Spertus J, Fajadet J, Mauri L, Schofer J, Verheye S, Dens J, Thuesen L, Dubois C, Hoffmann R, Wijns W, Fitzgerald PJ, Popma JJ, Macours N, Cebrian A, Stoll HP, Rogers C, Spaulding C,. Six-month results of the NEVO Res-Elution I (NEVO RES-I) trial: A randomized, multicenter comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Liberte paclitaxel-eluting stent in de novo native coronary artery lesions. Circ Cardiovasc Interv 2010; 3: 556-564.
59. Han Y, Jing Q, Xu B, Yang L, Liu H, Shang X, Jiang T, Li Z, Zhang H, Li H, Qiu J, Liu Y, Li Y, Chen X, Gao R,. Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in «real-world» practice: 18-month clinical and 9-month angiographic outcomes. JACC Cardiovasc Interv 2009; 2: 303-309.
60. Dawkins KD,. The Element stent technology. Paper presented at EuroPCR; May 25-28,2010; Paris, France. Available at: http://www.pcronline.com/Lectures/ 2010/The-ELEMENT-stent-technology. Accessed May 29, 20.
61. Granada JF,. The Orbus-Neich EPC-coated bioabsorbable polymer sirolimus-eluting stent program. Paper presented at: Transcatheter Cardiovascular Therapeutics, San Francisco, CA; 2009. Available at: http://www.tctmd.com/txshow.asp?tid=939086&id=84030&trid&938634. Accessed October 13, 2009.
62. Rutsch W. Multi-center first-in-man stuy with the lowest known limus dose on the Elixir Medical myolimus eluting coronary stent system with a durable polymer: Nine month clinical and six month angiographic and IVUS follow-up. Paper presented at: EuroPCR, Barcelona, Spain; 2009.
63. Dani S, Kukreja N, Parikh P, Joshi H, Prajapati J, Jain S, Thanvi S, Shah B, Dutta JP,. Biodegradable-polymer-based, sirolimus-eluting Supralimus stent: 6-month angiographic and 30-month clinical follow-up results from the series I prospective study. EuroIntervention 2008; 4: 59-63.
64. Grube E, Schofer J, Hauptmann KE, Nickenig G, Curzen N, Allocco DJ, Dawkins KD,. A novel paclitaxel-eluting stent with an ultrathin abluminal biodegradable polymer 9-month outcomes with the JACTAX HD stent. JACC Cardiovasc Interv 2010; 3: 431-438.
65. Vranckx P, Serruys PW, Gambhir S, Sousa E, Abizaid A, Lemos P, Ribeiro E, Dani SI, Dalal JJ, Mehan V, Dhar A, Dutta AL, Reddy KN, Chand R, Ray A, Symons J,. Biodegradable-polymer-based, paclitaxel-eluting Infinnium stent: 9-Month clinical and angiographic follow-up results from the SIMPLE II prospective multi-centre registry study. EuroIntervention 2006; 2: 310-317.
66. Onuma Y, Serruys P, den Heijer P, Joesoef KS, Duckers H, Regar E, Kukreja N, Tanimoto S, Garcia-Garcia HM, van Beusekom H, van der Giessen W, Nishide T,. MAHOROBA, first-in-man study: 6-month results of a biodegradable polymer sustained release tacrolimus-eluting stent in de novo coronary stenoses. Eur Heart J 2009; 30: 1477-1485.
67. Verheye S, Agostoni P, Dubois CL, Dens J, Ormiston J, Worthley S, Trauthen B, Hasegawa T, Koo BK, Fitzgerald PJ, Mehran R, Lansky AJ,. 9-month clinical, angiographic, and intravascular ultrasound results of a prospective evaluation of the Axxess self-expanding biolimus A9-eluting stent in coronary bifurcation lesions: The DIVERGE (Drug-Eluting Stent Intervention for Treating Side Branches Effectively) study. J Am Coll Cardiol 2009; 53: 1031-1039.
68. Stella PR, Mueller R, Pavlakis G, De Bruyne B, Hauptmann K, Morice MC, Chevalier B, Fajadet J, Sievert H, Grube E,. One year results of a new in situ length-adjustable stent platform with a biodegradable biolimus A9 eluting polymer: Results of the CUSTOM-II trial. EuroIntervention 2008; 4: 200-207.
69. Ielasi A, Latib A, Colombo A,. Current and future drug-eluting coronary stent technology. Expert Rev Cardiovasc Ther 2011; 9: 485-503.
70. Raber L, Windecker S,. Current status of drug-eluting stents. Cardiovasc Ther 2011; 29: 176-189.
71. Grube E,. BioFreedom First In Man progress report. Paper presented at: Transcatheter Cardiovascular Therapeutics, San Francisco, CA; 2009. Available at: http://www.tctmd.com/txshow.aspx?tid=941378&ij=84088&trid=938634. Accessed November 10, 2009.
72. Costa JR, Jr., Abizaid A, Costa R, Feres F, Tanajura LF, Maldonado G, Staico R, Siqueira D, Sousa AG, Bonan R, Sousa JE,. 1-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: The VESTASYNC I trial. JACC Cardiovasc Interv 2009; 2: 422-427.
73. Mehilli J, Kastrati A, Wessely R, Dibra A, Hausleiter J, Jaschke B, Dirschinger J, Schomig A,. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation 2006; 113: 273-279.
74. Abizaid A. PAX A trial (Amazonia PAX versus TAXUS Liberté): 4-month follow-up: IVUS and optical coherence tomography evaluation. Paper presented at: EuroPCR, Paris, France; 2010. Available at: http://www.pcronline. com/Lectures/2010/PAX-A-trial-Amazonia-PAX-versus-TAXUS-Liberte-4-month-follow- up-IVUS-and-optical-coherence-tomography-evaluation. Accessed May 29, 2010.
75. Morice MC, Bestehorn HP, Carrie D, Macaya C, Aengevaeren W, Wijns W, Dubois C, de Winter R, Verheye S, Hoffmann S, Pachinger O, Di Mario C,. Direct stenting of de novo coronary stenoses with tacrolimus-eluting versus carbon-coated carbostents. The randomized JUPITER II trial. EuroIntervention 2006; 2: 45-52.
76. Tang C, Wang G, Shen Y, Wan L, Xiao L, Zhang Q, Yu Q, Liu L, Wen G,. A study on surface endothelialization of plasma coated intravascular stents. Surf Coat Technol 2010; 204: 1487-1492.
77. Shen Y, Wang G, Chen L, Li H, Yu P, Bai M, Zhang Q, Lee J, Yu Q,. Investigation of surface endothelialization on biomedical nitinol (NiTi) alloy: Effects of surface micropatterning combined with plasma nanocoatings. Acta Biomater 2009; 5: 3593-3604.
78. Beijk MAM, Klomp M, Verouden NJW, Van Geloven N, Koch KT, Henriques JPS, Baan J, Vis MM, Scheunhage E, Piek JJ,. Genous™ endothelial progenitor cell capturing stent vs. The Taxus Liberté stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: A randomized, single-centre, pilot study. Eur Heart J 2010; 31: 1055-1064.
79. Blindt R, Vogt F, Astafieva I, Fach C, Hristov M, Krott N, Seitz B, Kapurniotu A, Kwok C, Dewor M, Bosserhoff AK, Bernhagen J, Hanrath P, Hoffmann R, Weber C,. A novel drug-eluting stent coated with an integrin-binding cyclic Arg-Gly-Asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells. J Am Coll Cardiol 2006; 47: 1786-1795.
80. Stefanadis C, Toutouzas K, Stefanadi E, Kolodgie F, Virmani R, Kipshidze N,. First experimental application of bevacizumab-eluting PC coated stent for inhibition of vasa vasorum of atherosclerotic plaque: Angiographic results in a rabbit atheromatic model. Hellenic J Cardiol 2006; 47: 7-10.
81. Pendyala L, Yin X, Li J, Shinke T, Xu Y, Chen J, King S 3rd, Colley K, Goodchild T, Chronos N,. Polymer-free cerivastatin-eluting stent shows superior neointimal inhibition with preserved vasomotor function compared to polymer-based paclitaxel-eluting stent in rabbit iliac arteries. EuroIntervention 2010; 6: 126-133.
82. Luo C, Zheng Y, Diao Z, Qiu J, Wang G,. Review: Research progress and future prospects for promoting endothelialization on endovascular stents and preventing restenosis. J Med Biol Eng 2011; 31: 307-316.
83. Granada JF, Inami S, Aboodi MS, Tellez A, Milewski K, Wallace-Bradley D, Parker S, Rowland S, Nakazawa G, Vorpahl M, Kolodgie FD, Kaluza GL, Leon MB, Virmani R,. Development of a novel prohealing stent designed to deliver sirolimus from a biodegradable abluminal matrix. Circ Cardiovasc Interv 2010; 3: 257-266.
84. Tang C, Wang G, Wu X, Li Z, Shen Y, Lee JC, Yu Q,. The impact of vascular endothelial growth factor-transfected human endothelial cells on endothelialization and restenosis of stainless steel stents. J Vasc Surg 2011; 53: 461-471.
85. Wu X, Wang G, Tang C, Zhang D, Li Z, Du D, Zhang Z,. Mesenchymal stem cell seeding promotes reendothelialization of the endovascular stent. J Biomed Mater Res A 2011; 98: 442-449.
86. Waksman R,. Biodegradable stents: They do their job and disappear. J Invasive Cardiol 2006; 18: 70-74.
87. Agrawal CM, Haas KF, Leopold DA, Clark HG,. Evaluation of poly(L-lactic acid) as a material for intravascular polymeric stents. Biomaterials 1992; 13: 176-182.
88. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, Nieman K, Bruining N, Dorange C, Miquel-Hebert K, Veldhof S, Webster M, Thuesen L, Dudek D,. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009; 373: 897-910.
89. Tanimoto S, Serruys PW, Thuesen L, Dudek D, de Bruyne B, Chevalier B, Ormiston JA,. Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: Insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv 2007; 70: 515-523. (Pubitemid 47597022)
90. Garg S, Serruys PW,. Coronary stents: Looking forward. J Am Coll Cardiol 2010; 56: S43-78.
91. Okamura T, Garg S, Gutierrez-Chico JL, Shin ES, Onuma Y, Garcia-Garcia HM, Rapoza RJ, Sudhir K, Regar E, Serruys PW,. In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: An OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial. EuroIntervention 2010; 5: 932-938.
92. Balcon R, Beyar R, Chierchia S, De Scheerder I, Hugenholtz PG, Kiemeneij F, Meier B, Meyer J, Monassier JP, Wijns W,. Recommendations on stent manufacture, implantation and utilization. Study Group of the Working Group on Coronary Circulation. Eur Heart J 1997; 18: 1536-1547.
93. Heublein B, Rohde R, Kaese V, Niemeyer M, Hartung W, Haverich A,. Biocorrosion of magnesium alloys: A new principle in cardiovascular implant technology? Heart 2003; 89: 651-656. (Pubitemid 36606211)
94. Waksman R, Erbel R, Di Mario C, Bartunek J, de Bruyne B, Eberli FR, Erne P, Haude M, Horrigan M, Ilsley C, Bose D, Bonnier H, Koolen J, Luscher TF, Weissman NJ,. Early- and long-term intravascular ultrasound and angiographic findings after bioabsorbable magnesium stent implantation in human coronary arteries. JACC Cardiovasc Interv 2009; 2: 312-320.
95. Erbel R, Di Mario C, Bartunek J, Bonnier J, de Bruyne B, Eberli FR, Erne P, Haude M, Heublein B, Horrigan M, Ilsley C, Bose D, Koolen J, Luscher TF, Weissman N, Waksman R,. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: A prospective, non-randomised multicentre trial. Lancet 2007; 369: 1869-1875. (Pubitemid 46829357)
96. Waksman R, Pakala R, Kuchulakanti PK, Baffour R, Hellinga D, Seabron R, Tio FO, Wittchow E, Hartwig S, Harder C, Bosserhoff AK, Bernhagen J, Hanrath P, Hoffmann R, Weber C,. Safety and efficacy of bioabsorbable magnesium alloy stents in porcine coronary arteries. Catheter Cardiovasc Interv 2006; 68: 607-617; discussion 618-609. (Pubitemid 44546055)
97. Waksman R,. Current state of the absorbable metallic (magnesium) stent. EuroIntervention 2009; 5 (Suppl F): F94-F97.
98. Drynda A, Seibt J, Hassel T, Bach FW, Peuster M,. Biocompatibility of fluoride-coated magnesium-calcium alloys with optimized degradation kinetics in a subcutaneous mouse model. J Biomed Mater Res A 2013; 101: 33-43.
99. Hanzi AC, Gerber I, Schinhammer M, Loffler JF, Uggowitzer PJ,. On the in vitro and in vivo degradation performance and biological response of new biodegradable Mg-Y-Zn alloys. Acta Biomater 2010; 6: 1824-1833.
100. Peuster M, Wohlsein P, Brugmann M, Ehlerding M, Seidler K, Fink C, Brauer H, Fischer A, Hausdorf G,. A novel approach to temporary stenting: Degradable cardiovascular stents produced from corrodible metal-results 6-18 months after implantation into New Zealand white rabbits. Heart 2001; 86: 563-569. (Pubitemid 32999872)
101. Peuster M, Hesse C, Schloo T, Fink C, Beerbaum P, von Schnakenburg C,. Long-term biocompatibility of a corrodible peripheral iron stent in the porcine descending aorta. Biomaterials 2006; 27: 4955-4962. (Pubitemid 43866928)
102. Waksman R, Pakala R, Baffour R, Seabron R, Hellinga D, Tio FO,. Short-term effects of biocorrodible iron stents in porcine coronary arteries. J Interv Cardiol 2008; 21: 15-20. (Pubitemid 351178402)
103. Hermawan H, Dube D, Mantovani D,. Degradable metallic biomaterials: Design and development of Fe-Mn alloys for stents. J Biomed Mater Res A 2010; 93: 1-11.
104. Hermawan H, Purnama A, Dube D, Couet J, Mantovani D,. Fe-Mn alloys for metallic biodegradable stents: Degradation and cell viability studies. Acta Biomater 2010; 6: 1852-1860.
105. Moravej M, Prima F, Fiset M, Mantovani D,. Electroformed iron as new biomaterial for degradable stents: Development process and structure-properties relationship. Acta Biomater 2010; 6: 1726-1735.
106. Moravej M, Purnama A, Fiset M, Couet J, Mantovani D,. Electroformed pure iron as a new biomaterial for degradable stents: In vitro degradation and preliminary cell viability studies. Acta Biomater 2010; 6: 1843-1851.
107. Moravej M, Amira S, Prima F, Rahem A, Fiset M, Mantovani D,. Effect of electrodeposition current density on the microstructure and the degradation of electroformed iron for degradable stents. Mat Sci Eng: B 2011; 176: 1812-1822.
108. Chen SL, Ye F, Zhang JJ, Tian NL, Liu ZZ, Santoso T, Zhou YJ, Jiang TM, Wen SY, Kwan TW,. Intravascular ultrasound-guided systematic two-stent techniques for coronary bifurcation lesions and reduced late stent thrombosis. Catheter Cardiovasc Interv 2013; 81: 456-463.
109. Ramcharitar S, Gonzalo N, van Geuns RJ, Garcia-Garcia HM, Wykrzykowska JJ, Ligthart JM, Regar E, Serruys PW,. First case of stenting of a vulnerable plaque in the SECRITT I trial-the dawn of a new era? Nat Rev Cardiol 2009; 6: 374-378.
110. Chamie D, Costa JR Jr, Abizaid A, Feres F, Staico R, Devito F, Costa RA, Tanajura LF, Sousa AG, Fitzgerald PJ, Whitbourn RJ, Sousa JE,. Serial angiography and intravascular ultrasound: Results of the SISC Registry (Stents In Small Coronaries). JACC Cardiovasc Interv 2010; 3: 191-202.